Latest stories on VKTX
Viking Therapeutics (VKTX) Reports Q3 $183M Loss Amid Rising R&D Costs
GuruFocus34 · bearishearnings
Viking Therapeutics quarterly net loss doubles as R&D expenses surge
Seeking Alpha34 · bearishearnings
Viking Therapeutics reports Q3 EPS ($1.55), consensus ($1.06)
The Fly74 · bullishearnings
Viking Therapeutics GAAP EPS of -$1.55 misses by $0.50
Seeking Alpha34 · bearishearnings
Viking Therapeutics, Inc. (VKTX) files 8-K
SEC 8-K50 · neutralgeneral
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire64 · neutralearnings
Viking Therapeutics options imply 6.6% move in share price post-earnings
The Fly50 · neutralearnings
Viking Therapeutics (VKTX) Set to Report Q3 Earnings Amid Mixed Guru and Insider Activity
GuruFocus50 · neutralearnings
Why Viking Therapeutics’ Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
24/7 Wall St.42 · neutralearnings
Viking Therapeutics put volume heavy and directionally bearish
The Fly34 · bearishgeneral
Viking Therapeutics sets Oct. 28 earnings date with Phase 3 obesity program VK2735 in focus
October 22, 2026
MarketChameleon53 · neutralearnings
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
PR Newswire50 · neutralgeneral
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years
The Motley Fool57 · neutralgeneral
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
The Motley Fool58 · neutralproduct/pr
Canaccord cuts Viking Therapeutic stock price target on obesity pricing
Investing.com Analyst Ratings34 · bearishanalyst
Viking Therapeutics price target lowered to $106 from $114 at Canaccord
The Fly38 · neutralanalyst
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
The Motley Fool42 · neutralgeneral
Viking Therapeutics initiated with a Buy at UBS
The Fly63 · neutralanalyst
Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
Stocktwits News74 · bullishproduct/pr
Viking Therapeutics begins Sunrise Phase 3 clinical program
The Fly58 · neutralproduct/pr
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
PR Newswire64 · neutralproduct/pr
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.
The Motley Fool74 · bullishanalyst
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
The Motley Fool58 · neutralproduct/pr
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Yahoo Finance56 · neutralgeneral
Viking Therapeutics price target lowered to $85 from $87 at Truist
The Fly42 · neutralanalyst